Japanese drug major Astellas Pharma (TYO: $4503) has announced two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. 4 April 2019
French privately-held biotech firm Enterome Bioscience has named Jan Fagerberg its new chief medical officer and Catherine Mathis its chief development officer. 3 April 2019
Daniel Welch, the man who previously headed up several biotechs that were sold to pharma majors over the past several years, has joined privately-held US biopharma company InCarda Therapeutics as executive chairman. 3 April 2019
Botox (onabotulinumtoxinA) manufacturer Allergan has accepted calls to shake up its management structure, agreeing to create a new position to stand alongside the chief executive at the time of the next leadership change. 25 March 2019
California, USA-based biopharma company Tenaya Therapeutics, which is focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team. 14 March 2019
Richard Francis will be stepping down as chief executive of Sandoz, the Novartis generics and biosimilars division, and as a member of the executive committee of Novartis on March 31, 2019. 14 March 2019
Keld Flintholm Jørgensen has been appointed chief business officer (CBO) heading corporate strategy and business development at Danish CNS specialist Lundbeck. 8 March 2019
Indian drugmaker Glenmark Pharmaceuticals has announced that Alessandro Riva will join its new innovation company as chief executive. The appointment is effective April 2, 2019. 7 March 2019
Dutch biopharma Kiadis Pharma today announced senior management appointments to further strengthen the company as it transitions into commercial stage. 6 March 2019
USA-based Corbus Pharmaceutical has announced the appointment of Craig Millian to the company as its first chief commercial officer ahead of the potential US Food and Drug Administration approval and commercial launch of its lead drug candidate lenabasum in 2021. 5 March 2019
US-based Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, has appointed Antony Loebel as president and chief executive. 5 March 2019
UK-based biotech firm Emergex Vaccines today announces the appointment of Athanasios Papadopoulos as chief medical officer, effective March 1, 2019. 27 February 2019
A woman who has been involved in biosimilars since work on their development first began two decades ago, has been named director general of the International Generic and Biosimilar medicines Association (IGBA). 21 February 2019
The UK’s BioIndustry Association (BIA) chairwoman Dr Jane Osbourn has announced this week that she is to leave AstraZeneca after 25 years with Cambridge Antibody Technology and MedImmune, where she is vice president R&D and site leader, the trade group announced yesterday. 19 February 2019
Mundipharma has appointed Patrice Grand as European director of corporate communications, reporting to Alberto Martinez, president and chief executive in Europe. 18 February 2019
Spanish family-owned drugmaker Esteve has appointed Jordi Muntañola as the new chief commercial officer for Europe, taking on the leadership of all the pharmaceutical activities in Spain and Europe. 15 February 2019
Privately-held French drugmaker Pierre Fabre Group has appointed Maarten Kraan to the position of director of research and development for Pierre Fabre Pharmaceuticals (PFM), reporting to Frédéric Duchesne, chief executive of the Pharmaceuticals Division, and will sit on the branch’s executive committee. 8 February 2019
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024